v3.25.3
Segment Information
 9 Months Ended
Sep. 30, 2025
Segment Reporting [Abstract]  
Segment Information Segment Information
The Company operates as a single operating segment that is engaged in discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. A global research and development organization and a supply chain organization discover, develop, manufacture, and supply our products. A global commercial organization markets, distributes, and sells the products. The business is also supported by global corporate staff functions. The Company’s Chief Operating Decision Maker (the “CODM”) is the Chief Executive Officer, who assesses performance and allocates resources based on significant expenses and net income on a consolidated basis. The significant expenses that are regularly provided to the CODM include those amounts that are also reported on the consolidated statement of operations as well as below additional disaggregated measures. The CODM also reviews cash position (which are cash and cash equivalents, current restricted cash, and short-term investments) that are also reported on the consolidated balance sheets when making operating decisions. In accordance with ASC 280, the Company has only one reportable segment.
The following tables present disaggregated expenses that are regularly provided to the CODM:
Three Months Ended September 30,Nine Months Ended September 30,
2025202420252024
Personnel compensation and related costs21,539 23,405 68,067 82,622 
Licensing fees— 22,634 19,997 22,634 
CROs/CMOs/Investigators expenses18,707 13,004 48,472 57,213 
Other costs7,682 6,939 22,735 19,783 
Total research and development expenses47,928 65,982 159,271 182,252 
Three Months Ended September 30,Nine Months Ended September 30,
2025202420252024
Clinical programs18,179 23,060 63,236 63,196 
Pre-Clinical programs1,982 14,461 10,365 19,649 
Unallocated research and development expenses27,767 28,461 85,670 99,407 
Total research and development expenses47,928 65,982 159,271 182,252 

Three Months Ended September 30,Nine Months Ended September 30,
2025202420252024
Personnel compensation and related costs41,320 39,984 124,642 134,157 
Other costs28,786 27,235 79,924 81,966 
Total selling, general, and administrative expenses70,106 67,219 204,566 216,123 
Three Months Ended September 30,Nine Months Ended September 30,
2025202420252024
Selling and marketing expenses47,179 43,473 135,882 140,342 
General and administrative expenses22,927 23,746 68,684 75,781 
Total selling, general, and administrative expenses70,106 67,219 204,566 216,123